文献速递产科母胎医学

氯己定与安慰剂术前阴道清洁在胎膜早破患者中的比较:一项前瞻性、随机、双盲、安慰剂对照研究

Preoperative vaginal cleansing with chlorhexidine vs placebo in patients with rupture of membranes: a prospective, randomized, double-blind, placebo-control study.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-01-17

该前瞻性随机双盲安慰剂对照研究纳入204例胎膜早破或破膜后产程超过6小时的剖宫产患者,比较术前4%氯己定阴道清洁与生理盐水安慰剂的感染预防效果。氯己定组子宫内膜炎和产褥热发生率显著低于安慰剂组,但手术部位感染无显著差异,住院超过72小时的差异置信区间提示可能为偶然。

要点

  • 氯己定组子宫内膜炎发生率7.21% vs 安慰剂组18.8%,相对风险0.39(95%CI 0.17-0.87,P=.015)。
  • 氯己定组产褥热发生率9.28% vs 安慰剂组19.8%,相对风险0.47(95%CI 0.23-0.98,P=.037)。
  • 手术部位感染在术后7天和15天均无显著差异。

核心结论

  • 剖宫产术前使用氯己定阴道清洁可降低胎膜早破患者子宫内膜炎和产褥热的风险,对手术部位感染无影响。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照研究,共纳入204例胎膜早破或破膜后产程超过6小时行剖宫产的患者,氯己定组97例,安慰剂组107例。

主要发现

  • 氯己定组子宫内膜炎发生率7.21% vs 安慰剂组18.8%,相对风险0.39(95%CI 0.17-0.87,P=.015)。
  • 氯己定组产褥热发生率9.28% vs 安慰剂组19.8%,相对风险0.47(95%CI 0.23-0.98,P=.037)。
  • 住院超过72小时发生率氯己定组1.03% vs 安慰剂组7.55%,相对风险0.14(95%CI 0.02-1.08,P=.02),但置信区间提示效应可能为偶然。
  • 术后7天手术部位感染氯己定组1.03% vs 安慰剂组0.94%,相对风险1.1(95%CI 0.07-17.4,P=.94),无统计学差异。
  • 术后15天手术部位感染氯己定组1.03% vs 安慰剂组0%,相对风险3.31(使用连续性校正,95%CI 0.14-80.21,P=.29),无统计学差异。

临床怎么用

  • 作者结论认为,剖宫产术前氯己定阴道清洁可降低胎膜早破患者子宫内膜炎和产褥热风险,并减少住院超过3天的病例数,但对手术部位感染无影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: XXX OBJECTIVE: This study aimed to demonstrate that vaginal cleansing with a 4% chlorhexidine solution before cesarean delivery in patients with a history of rupture of membranes prevents postoperative infectious complications (endometritis, surgical site infections). STUDY DESIGN: A total of 204 patients with premature rupture of membranes or who were in labor for more than 6 hours after membranes ruptured were randomized before a cesarean delivery to preoperative vaginal cleansing with a chlorhexidine solution (n=97 patients) or to placebo cleansing with saline solution (n=107 patients). The management of the rupture of membranes and the cesarean delivery procedure were conducted according to standard local protocols for both groups, including the use of antibiotics. RESULTS: Vaginal cleansing with chlorhexidine reduced the risk for endometritis after cesarean delivery in patients with rupture of membranes when compared with placebo cleansing (chlorhexidine, 7.21% vs placebo, 18.8%; relative risk, 0.39; 95% confidence interval, 0.17-0.87; P=.015). Likewise, there was a statistically significant reduction in the number of cases of puerperal fever (chlorhexidine, 9.28% vs placebo, 19.8%; relative risk, 0.47; 95% confidence interval, 0.23-0.98; P=.037). There was a statistical difference between the groups in prolongation of hospitalization for >72 hours (chlorhexidine, 1.03% vs placebo, 7.55%; relative risk, 0.14; 95% confidence interval, 0.02-1.08; P=.02), although the confidence interval suggests that the effect was by chance. There were no statistical differences in surgical site infection at 7 days (chlorhexidine, 1.03% vs placebo, 0.94%; relative risk, 1.1; 95% confidence interval, 0.07-17.4; P=.94) and 15 days after the procedure (chlorhexidine, 1.03% vs placebo, 0%; relative risk, 3.31 [using a continuity correction]; 95% confidence interval, 0.14-80.21; P=.29). CONCLUSION: The use of chlorhexidine for vaginal cleansing before a cesarean delivery in patients with rupture of membranes reduced the risk for endometritis and puerperal fever. It also reduced the number of cases that required hospitalization for more than 3 days, but the confidence interval suggests that it could be by chance. It has no effect on the number of cases with surgical site infection.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Ureña N, Reyes O. Preoperative vaginal cleansing with chlorhexidine vs placebo in patients with rupture of membranes: a prospective, randomized, double-blind, placebo-control study. Am J Obstet Gynecol MFM. 2022. PMID: 35051671. doi:10.1016/j.ajogmf.2022.100572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。